骨髓增生异常综合征骨髓原始细胞祖细胞体外培养  

TREATMENT OF MYELCOYSPLASTIC SYNDROMES ANDITS SECONDARY ACUTE MYELOID LEUKEMIAS WITHORDINARY DOSE COMBINATION CHEMOTHERAPY

作　　者：张新友[1] 郝玉书[1] 徐国珠[1] 姜学英[1] 张新民[1] 赵英新[1] 

机构地区：[1]中国医学科学院协和医科大学血液学研究所,深圳市人民医院

出　　处：《中华血液学杂志》1994年第7期345-348,共4页Chinese Journal of Hematology

摘　　要：以植物血凝素－白细胞条件培养液（ＰＨＡ－ＬＣＭ）作为刺激源，研究确定了白血病原始细胞祖细胞（ＢＣＰ）体外培养方法的一些细节。用此方法观察了骨髓增生异常综合征（ＭＤＳ）患者去除Ｔ细胞和粘附细胞的骨髓单个核细胞中ＢＣＰ体外生长情况。２７例ＭＤＳ中１０例（３７％）有原始细胞集落（ＢＣＣ）生长。ＢＣＣ阳性率和产率与ＦＡＢ亚型之间有一定的相关性；阳性率并与姐妹染色单体分化（ＳＣＤ）显著相关。对照组中无一例有ＢＣＣ生长。本文结果表明ＢＣＰ能够反映ＭＤＳ的恶性细胞克隆；ＢＣＣ是评估ＭＤＳ病期的重要生物学指标。he treatment of myeledysplastic syndromes(MDS)and its secondary acute myeloid leukemias(SAML)isstill a difficult problem in clinical practice, and there isstill much controversy over the role for ordinary dose ofcombination chemotherapy (ODCC) in the disease. Wereported our results of treatment of 7 MDS and 11SAML patients with ODCC. The complete remissionrate was 35% and partial remission rate 12%. Only twotherapy-related death occurred in the whole group. Weconcluded that it was feasible to treat selected cases ofMDS with ODCC.

关 键 词：骨髓增生异常 综合征 原始细胞集落 

分 类 号：R551.3[医药卫生—血液循环系统疾病]